Description of Research Expertise:
Cancer immunotherapy
Vaccines
Cellular therapy
Phase I trials
CAR T cells
Selected Publications:
Cohen, A D., Garfall, A L., Stadtmauer, E A., Melenhorst, J. J, Lacey, Simon F., Lancaster, E, Vogl, D T., Weiss, B M., Dengel, K, Nelson, A, Plesa, G, Chen, F, Davis, M M., Hwang, Wei-Ting, Young, R M., Brogdon, J L., Isaacs, R, Pruteanu-Malinici, I, Siegel, D L., Levine, B L., June, C H., Milone, M C.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma The Journal of Clinical Investigation : doi: 10.1172/JCI126397,2019.
Susanibar Adaniya, S P., Cohen, A D.*, Garfall, A L.*: Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications American Journal of Hematology doi: 10.1002/ajh.25428 (0): 2019.
Trudel, S, Lendvai, N, Popat, R, Voorhees, P M., Reeves, B, Libby, E N., Richardson, P G., Hoos, A, Gupta, I, Bragulat, V, He, Z, Opalinska, J B., Cohen, A D.: Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer Journal 9 (4): 37,2019.
Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ.: Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma Cancer Immunology Research 7 (4): 658-669,2019.
L Bernabei, A L. Garfall, J. J Melenhorst, S F Lacey, E A. Stadtmauer, D T. Vogl, V Gonzalez, G Plesa, R M Young, A Waxman, B L Levine, C H June, M C. Milone, and A D. Cohen: PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after BCMA-Directed CAR T Cells Blood, ASH Annual Meeting, San Diego, CA 132 : #1973,2018.
E Dancy, A L. Garfall, A D. Cohen, J A Fraietta, M Davis, B L Levine, D L. Siegel, E A. Stadtmauer, D T. Vogl, A Waxman, A P. Rapoport, M C. Milone, C H June, and J. J Melenhorst: Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma Blood, ASH Annual Meeting, San Diego, CA 132 : #1886,2018.
Tara Gregory, Adam D. Cohen, Caitlin L. Costello, Syed Abbas Ali, Jesus G. Berdeja, Eric M Ostertag, Christopher Martin, Devon J Shedlock, Michelle Lynn Resler, Matthew A. Spear, Robert Z. Orlowski, and Krina K. Patel: Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) Blood, ASH Annual Meeting, San Diego, CA 132 : #1012,2018.
Adam D. Cohen, J. Joseph Melenhorst, Alfred L. Garfall, Simon F Lacey, Megan Davis, Dan T. Vogl, Lifeng Tian, Vanessa Gonzalez, Iulian Pruteanu, Anne Marie Nelson, Gabriela Plesa, Adam Waxman, Regina M Young, Bruce L Levine, Carl H June, Edward A. Stadtmauer, and Michael C. Milone: Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM) Blood, ASH Annual Meeting, San Diego, CA 132 : #1974,2018.
A.D. Cohen: CAR T-cell therapy against B-cell maturation antigen in multiple myeloma Clinical Advances in Hematology and Oncology 16 (12): 804-806,2018.
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson Jr. LD, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD: Targeting B-Cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma: A Dose-Escalation and Expansion Phase 1 Trial (BMA117159) Lancet Oncology pii: S1470-2045 (18): 30576-X,2018.